The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
This study evaluated BGB-16673, an investigational drug that degrades the BTK protein, in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), whose disease had transformed into a more aggressive form (Richter transformation) and who had tried several prior treatments. Among 24 patients, BGB-16673 was generally tolerable, with manageable side effects. Two-thirds of patients had grade ≥3 treatment-emergent adverse events (TEAEs). TEAEs of any grade that occurred in ≥15% of patients were decreased neutrophil count, nausea, diarrhea, peripheral edema, and pneumonia. One death occurred but was a result to the disease progressing, not due to treatment. About half responded to treatment, with some responses lasting more than six months. Responses were also observed in patients with high-risk genetic mutations. These results support further investigation of BGB-16673 in Richter transformation.
